4th international conference on tumor progression and therapeutic resistance: meeting report

References

• Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79:7824-7; PMID:6961453; http://dx.doi.org/10.1073/pnas.79.24.7824
   PubMed Web of Science ®Google Scholar
• Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007; 4:359-65; PMID:17396127; http://dx.doi.org/10.1038/nmeth1015
   PubMed Web of Science ®Google Scholar
• Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997; 137:231-45; PMID:9105051; http://dx.doi.org/10.1083/jcb.137.1.231
   PubMed Web of Science ®Google Scholar
• Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci 2002; 115:39-50; PMID:11801722
   PubMed Web of Science ®Google Scholar
• Spencer VA, Costes S, Inman JL, Xu R, Chen J, Hendzel MJ, Bissell MJ. Depletion of nuclear actin is a key mediator of quiescence in epithelial cells. J Cell Sci 2011; 124:123-32; PMID:21172822; http://dx.doi.org/10.1242/jcs.073197
   PubMed Web of Science ®Google Scholar
• Onodera Y, Nam JM, Bissell MJ. Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J Clin Invest 2014; 124:367-84; PMID:24316969; http://dx.doi.org/10.1172/JCI63146
   PubMed Web of Science ®Google Scholar
• Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39:347-51; PMID:17293865; http://dx.doi.org/10.1038/ng1975
   PubMed Web of Science ®Google Scholar
• MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009; 4:e7887; PMID:19924296; http://dx.doi.org/10.1371/journal.pone.0007887
   PubMed Web of Science ®Google Scholar
• Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2:82-93; PMID:22585170; http://dx.doi.org/10.1158/2159-8290.CD-11-0184
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-703; PMID:23020132; http://dx.doi.org/10.1056/NEJMoa1210093
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014; 4:94-109; PMID:24265153; http://dx.doi.org/10.1158/2159-8290.CD-13-0617
   PubMed Web of Science ®Google Scholar
• Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014; 4:61-8; PMID:24265154; http://dx.doi.org/10.1158/2159-8290.CD-13-0631
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. Prostate Cancer Prostatic Dis 2014; 17:23-7; PMID:24366412; http://dx.doi.org/10.1038/pcan.2013.37
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968-72; PMID:21107320; http://dx.doi.org/10.1038/nature09627
   PubMed Web of Science ®Google Scholar
• Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280:1614-7; PMID:9616126; http://dx.doi.org/10.1126/science.280.5369.1614
   PubMed Web of Science ®Google Scholar
• Hodakoski C, Hopkins BD, Barrows D, Mense SM, Keniry M, Anderson KE, Kern PA, Hawkins PT, Stephens LR, Parsons R. Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. Proc Natl Acad Sci U S A 2014; 111:155-60; PMID:24367090; http://dx.doi.org/10.1073/pnas.1213773111
   PubMed Web of Science ®Google Scholar
• Donald S, Humby T, Fyfe I, Segonds-Pichon A, Walker SA, Andrews SR, Coadwell WJ, Emson P, Wilkinson LS, Welch HC. P-Rex2 regulates Purkinje cell dendrite morphology and motor coordination. Proc Natl Acad Sci U S A 2008; 105:4483-8; PMID:18334636; http://dx.doi.org/10.1073/pnas.0712324105
   PubMed Web of Science ®Google Scholar
• Kuznetsov HS, Marsh T, Markens BA, Castano Z, Greene-Colozzi A, Hay SA, Brown VE, Richardson AL, Signoretti S, Battinelli EM, et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2012; 2:1150-65; PMID:22896036; http://dx.doi.org/10.1158/2159-8290.CD-12-0216
   PubMed Web of Science ®Google Scholar
• McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander BL, Repasky EA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133:994-1005; PMID:18555776; http://dx.doi.org/10.1016/j.cell.2008.04.045
   PubMed Web of Science ®Google Scholar
• Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirstrom K, Magnusson K, Ebert BL, et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011; 121:784-99; PMID:21266779; http://dx.doi.org/10.1172/JCI43757
   PubMed Web of Science ®Google Scholar
• Castano Z, Marsh T, Tadipatri R, Kuznetsov HS, Al-Shahrour F, Paktinat M, Greene-Colozzi A, Nilsson B, Richardson AL, McAllister SS. Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov 2013; 3:922-35; PMID:23689072; http://dx.doi.org/10.1158/2159-8290.CD-13-0041
   PubMed Web of Science ®Google Scholar
• Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38:1060-5; PMID:16878133; http://dx.doi.org/10.1038/ng1855
   PubMed Web of Science ®Google Scholar
• Janz A, Sevignani C, Kenyon K, Ngo CV, Thomas-Tikhonenko A. Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res 2000; 28:2268-75; PMID:10871348; http://dx.doi.org/10.1093/nar/28.11.2268
   PubMed Web of Science ®Google Scholar
• Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, et al. The myc-miR-17∼92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res 2010; 70:8233-46; PMID:20940405; http://dx.doi.org/10.1158/0008-5472.CAN-10-2412
   PubMed Web of Science ®Google Scholar
• Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, von Stedingk K, Ghesquiere B, Schulte S, Dews M, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 2010; 40:762-73; PMID:21145484; http://dx.doi.org/10.1016/j.molcel.2010.11.038
   PubMed Web of Science ®Google Scholar
• Dews M, Tan GS, Hultine S, Raman P, Choi J, Duperret EK, Lawler J, Bass A, Thomas-Tikhonenko A. Masking Epistasis Between MYC and TGF-beta Pathways in Antiangiogenesis-Mediated Colon Cancer Suppression. J Natl Cancer Inst 2014; PMID:24627270
   PubMed Web of Science ®Google Scholar
• Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Ruvolo P, et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-kappaB mediates chemoresistance. Blood 2014; PMID:24599548
   PubMed Web of Science ®Google Scholar
• Chen Y, Jacamo R, Shi YX, Wang RY, Battula VL, Konoplev S, Strunk D, Hofmann NA, Reinisch A, Konopleva M, et al. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood 2012; 119:4971-80; PMID:22490334; http://dx.doi.org/10.1182/blood-2011-11-389957
   PubMed Web of Science ®Google Scholar
• Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest 2013; 123:2395-407; PMID:23676502; http://dx.doi.org/10.1172/JCI66553
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03.027
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011; 108:7950-5; PMID:21498687; http://dx.doi.org/10.1073/pnas.1102454108
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D'Alessio AC, Young RA, Weinberg RA. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154:61-74; PMID:23827675; http://dx.doi.org/10.1016/j.cell.2013.06.005
   PubMed Web of Science ®Google Scholar
• Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-59; PMID:19682730; http://dx.doi.org/10.1016/j.cell.2009.06.034
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A 2009; 106:10290-5; PMID:19502425; http://dx.doi.org/10.1073/pnas.0904227106
   PubMed Web of Science ®Google Scholar
• Shibue T, Brooks MW, Weinberg RA. An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell 2013; 24:481-98; PMID:24035453; http://dx.doi.org/10.1016/j.ccr.2013.08.012
   PubMed Web of Science ®Google Scholar
• Zabierowski SE, Fukunaga-Kalabis M, Li L, Herlyn M. Dermis-derived stem cells: a source of epidermal melanocytes and melanoma? Pigment Cell Melanoma Res 2011; 24:422-9; PMID:21410654; http://dx.doi.org/10.1111/j.1755-148X.2011.00847.x
   PubMed Web of Science ®Google Scholar
• Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 2005; 10:153-63; PMID:16358819; http://dx.doi.org/10.1111/j.1087-0024.2005.200407.x
   PubMed Web of Science ®Google Scholar
• Herlyn M, Fukunaga-Kalabis M. What is a good model for melanoma? J Invest Dermatol 2010; 130:911-2; PMID:20231823; http://dx.doi.org/10.1038/jid.2009.441
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-14; PMID:22356324; http://dx.doi.org/10.1056/NEJMoa1112302
   PubMed Web of Science ®Google Scholar
• Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Korbel C, Laschke MW, Gimotty PA, Philipp SE, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 2013; 23:811-25; PMID:23764003; http://dx.doi.org/10.1016/j.ccr.2013.05.003
   PubMed Web of Science ®Google Scholar
• Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A 2012; 109:2772-7; PMID:21940501; http://dx.doi.org/10.1073/pnas.1017626108
   PubMed Web of Science ®Google Scholar
• Skibinski A, Breindel JL, Prat A, Galvan P, Smith E, Rolfs A, Gupta PB, Labaer J, Kuperwasser C. The hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep 2014; 6:1059-72; PMID:24613358; http://dx.doi.org/10.1016/j.celrep.2014.02.038
   PubMed Web of Science ®Google Scholar
• Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, Gilmore H, Tung N, Naber SP, Schnitt S, et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011; 8:149-63; PMID:21295272; http://dx.doi.org/10.1016/j.stem.2010.12.007
   PubMed Web of Science ®Google Scholar
• Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 2009; 138:377-88; PMID:19632185; http://dx.doi.org/10.1016/j.cell.2009.05.022
   PubMed Web of Science ®Google Scholar
• Burikhanov R, Shrestha-Bhattarai T, Hebbar N, Qiu S, Zhao Y, Zambetti GP, Rangnekar VM. Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4. Cell Rep 2014; 6:271-7; PMID:24412360; http://dx.doi.org/10.1016/j.celrep.2013.12.020
   PubMed Web of Science ®Google Scholar
• Burikhanov R, Shrestha-Bhattarai T, Qiu S, Shukla N, Hebbar N, Lele SM, Horbinski C, Rangnekar VM. Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4. Cancer Res 2013; 73:1011-9; PMID:23204231; http://dx.doi.org/10.1158/0008-5472.CAN-12-3212
   PubMed Web of Science ®Google Scholar
• Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, Netto MM, Soares FA. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011; 126:1-14; PMID:20369286; http://dx.doi.org/10.1007/s10549-010-0867-2
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013; 49:1297-304; PMID:23290787; http://dx.doi.org/10.1016/j.ejca.2012.11.019
   PubMed Web of Science ®Google Scholar
• Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 2013; 110:4321-6; PMID:23447565; http://dx.doi.org/10.1073/pnas.1205575110
   PubMed Web of Science ®Google Scholar
• Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 2013; 23:302-15; PMID:23477830; http://dx.doi.org/10.1016/j.ccr.2013.02.003
   PubMed Web of Science ®Google Scholar
• Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM, et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013; 23:287-301; PMID:23416000; http://dx.doi.org/10.1016/j.ccr.2012.11.020
   PubMed Web of Science ®Google Scholar
• Patel N, Chatterjee SK, Vrbanac V, Chung I, Mu CJ, Olsen RR, Waghorne C, Zetter BR. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc Natl Acad Sci U S A 2010; 107:2503-8; PMID:20133800; http://dx.doi.org/10.1073/pnas.0910649107
   PubMed Web of Science ®Google Scholar
• Fels DR, Koumenis C. The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther 2006; 5:723-8; PMID:16861899; http://dx.doi.org/10.4161/cbt.5.7.2967
   PubMed Web of Science ®Google Scholar
• Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 2014; 124:1406-17; PMID:24569374; http://dx.doi.org/10.1172/JCI70454
   PubMed Web of Science ®Google Scholar
• Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194:23-8; PMID:959840; http://dx.doi.org/10.1126/science.959840
   PubMed Web of Science ®Google Scholar
• Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, et al. The life history of 21 breast cancers. Cell 2012; 149:994-1007; PMID:22608083; http://dx.doi.org/10.1016/j.cell.2012.04.023
   PubMed Web of Science ®Google Scholar
• Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 2014; 508:113-7; PMID:24695311; http://dx.doi.org/10.1038/nature13187
   PubMed Web of Science ®Google Scholar
• Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12:229-43; PMID:23449308; http://dx.doi.org/10.1038/nrd3937
   PubMed Web of Science ®Google Scholar
• Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 2014; 111:2349-54; PMID:24469833; http://dx.doi.org/10.1073/pnas.1311846111
   PubMed Web of Science ®Google Scholar
• Coleman R. The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci 2011; 1218:3-14; PMID:20946581; http://dx.doi.org/10.1111/j.1749-6632.2010.05766.x
   PubMed Web of Science ®Google Scholar
• Sakakibara M, Fujimori T, Miyoshi T, Nagashima T, Fujimoto H, Suzuki HT, Ohki Y, Fushimi K, Yokomizo J, Nakatani Y, et al. Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer. Cancer 2012; 118:3899-910; PMID:22180194; http://dx.doi.org/10.1002/cncr.26725
   PubMed Web of Science ®Google Scholar
• Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 2009; 69:466-74; PMID:19147559; http://dx.doi.org/10.1158/0008-5472.CAN-08-3078
   PubMed Web of Science ®Google Scholar
• Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71:3991-4001; PMID:21498635; http://dx.doi.org/10.1158/0008-5472.CAN-10-3175
   PubMed Web of Science ®Google Scholar
• Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010; 120:1515-23; PMID:20389021; http://dx.doi.org/10.1172/JCI40802
   PubMed Web of Science ®Google Scholar
• Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene 2012; 31:3148-63; PMID:22020330; http://dx.doi.org/10.1038/onc.2011.485
   PubMed Web of Science ®Google Scholar
• Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov 2013; 3:1044-57; PMID:23764425; http://dx.doi.org/10.1158/2159-8290.CD-12-0592
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462:108-12; PMID:19847166; http://dx.doi.org/10.1038/nature08460
   PubMed Web of Science ®Google Scholar
• Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, et al. Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit. Cancer Discov 2014; 4:452-65; PMID:24444711; http://dx.doi.org/10.1158/2159-8290.CD-13-0646
   PubMed Web of Science ®Google Scholar
• Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012; 151:1457-73; PMID:23245941; http://dx.doi.org/10.1016/j.cell.2012.11.026
   PubMed Web of Science ®Google Scholar
• Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014; 343:80-4; PMID:24336569; http://dx.doi.org/10.1126/science.1246981
   PubMed Web of Science ®Google Scholar
• Prabhu VV, Allen JE, Hong B, Zhang S, Cheng H, El-Deiry WS. Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets 2012; 16:1161-74; PMID:22998602; http://dx.doi.org/10.1517/14728222.2012.726985
   PubMed Web of Science ®Google Scholar
• Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets 2014; 15:80-9; PMID:24387333; http://dx.doi.org/10.2174/1389450114666140106101412
   PubMed Web of Science ®Google Scholar
• Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Puig P. Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer 2002; 100:131-5; PMID:12115559; http://dx.doi.org/10.1002/ijc.10480
   PubMed Web of Science ®Google Scholar
• El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25; PMID:8242752; http://dx.doi.org/10.1016/0092-8674(93)90500-P
   PubMed Web of Science ®Google Scholar
• Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30:3633-9; PMID:22965953; http://dx.doi.org/10.1200/JCO.2011.40.7783
   PubMed Web of Science ®Google Scholar
• Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A 2006; 103:11003-8; PMID:16835297; http://dx.doi.org/10.1073/pnas.0604507103
   PubMed Web of Science ®Google Scholar
• Lu C, Wang W, El-Deiry WS. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther 2008; 7:2039-46; PMID:19106635; http://dx.doi.org/10.4161/cbt.7.12.7461
   PubMed Web of Science ®Google Scholar
• Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L, El-Deiry WS. Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res 2014; 74:1153-65; PMID:24247721; http://dx.doi.org/10.1158/0008-5472.CAN-13-0955
   PubMed Web of Science ®Google Scholar
• Huang C, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W, El-Deiry WS. The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol Ther 2009; 8:2186-93; PMID:19923910; http://dx.doi.org/10.4161/cbt.8.22.10446
   PubMed Web of Science ®Google Scholar
• Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011; 333:1039-43; PMID:21852505; http://dx.doi.org/10.1126/science.1203619
   PubMed Web of Science ®Google Scholar
• Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013; 45:1428-30; PMID:24121789; http://dx.doi.org/10.1038/ng.2800
   PubMed Web of Science ®Google Scholar
• Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012; 4:162ra54; PMID:23197571; http://dx.doi.org/10.1126/scitranslmed.3004742
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6:224ra24; PMID:24553385; http://dx.doi.org/10.1126/scitranslmed.3007094
   PubMed Web of Science ®Google Scholar
• Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013; 3:658-73; PMID:23729478; http://dx.doi.org/10.1158/2159-8290.CD-12-0558
   PubMed Web of Science ®Google Scholar
• Ding X, Li P, Lin SC, Stratton ZS, Nama N, Guo F, Slotcavage D, Mao X, Shi J, Costanzo F, et al. Surface acoustic wave microfluidics. Lab Chip 2013; 13:3626-49; PMID:23900527; http://dx.doi.org/10.1039/c3lc50361e
   PubMed Web of Science ®Google Scholar
• Podlaha O, Riester M, De S, Michor F. Evolution of the cancer genome. Trends Genet 2012; 28:155-63; PMID:22342180; http://dx.doi.org/10.1016/j.tig.2012.01.003
   PubMed Web of Science ®Google Scholar
• Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. J Theor Biol 2014; 355C:10-20; PMID:24681298; http://dx.doi.org/10.1016/j.jtbi.2014.02.025
   PubMed Web of Science ®Google Scholar
• Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011; 3:90ra59; PMID:21734175; http://dx.doi.org/10.1126/scitranslmed.3002356
   PubMed Web of Science ®Google Scholar
• Leder K, Pitter K, Laplant Q, Hambardzumyan D, Ross BD, Chan TA, Holland EC, Michor F. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell 2014; 156:603-16; PMID:24485463; http://dx.doi.org/10.1016/j.cell.2013.12.029
   PubMed Web of Science ®Google Scholar